Optimizing gemcitabine regimens in ovarian cancer

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Pharmacology

Background:

• Ovarian cancer is the leading cause of death from gynecologic neoplasms.
• Secondary treatment options for recurrent or progressive ovarian cancer have limited efficacy.
• Gemcitabine is an emerging antineoplastic agent with demonstrated activity in various cancer types.

Purpose of the Study:

• To evaluate the efficacy and safety of gemcitabine as a secondary treatment for recurrent or progressive ovarian cancer.
• To assess the potential of gemcitabine in combination chemotherapy regimens for ovarian cancer.
• To clarify the clinical impact of adding a third drug to standard chemotherapy in a phase III trial.

Main Methods:

• Review of existing studies on gemcitabine in ovarian cancer.
• Analysis of phase I and II studies of first-line combination chemotherapy including gemcitabine.
• Description of the ongoing Gynecologic Oncology Group Protocol 182/International Collaborative Ovarian Neoplasm 5 study (a five-arm, randomized phase III trial).

Main Results:

• Gemcitabine exhibits significant activity and synergism with cisplatin.
• It shows a mild toxicity profile in platinum-sensitive, platinum-resistant, and taxane-pretreated recurrent/progressive ovarian cancer patients.
• Phase I and II studies indicate promising response rates with first-line gemcitabine-based combination chemotherapy.

Conclusions:

• Gemcitabine is a promising agent for secondary treatment of ovarian cancer, effective in various patient subgroups.
• Combination chemotherapy including gemcitabine warrants further investigation for improved treatment outcomes.
• The ongoing phase III study will provide crucial data on the optimal use of gemcitabine in ovarian cancer treatment.